

## Erratum

# Cenicriviroc ameliorates the severity of graft-versus host disease through inhibition of CCR5 in a rat model of liver transplantation: Am J Transl Res. 2019; 11(6): 3438-3449

Minhuan Li<sup>1\*</sup>, Chenglin Lu<sup>2\*</sup>, Hao Zhu<sup>3\*</sup>, Xing Kang<sup>2</sup>, Feng Wang<sup>2</sup>, Lihua Shao<sup>2</sup>, Xiaofeng Lu<sup>2</sup>, Wei Chen<sup>4</sup>, Xuefeng Xia<sup>2</sup>

<sup>1</sup>Center of Pathology and Clinical Laboratory, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211100, Jiangsu Province, China; Departments of <sup>2</sup>General Surgery, <sup>3</sup>Gastroenterology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China; <sup>4</sup>Cancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China. \*Equal contributors.

Received November 13, 2019; Accepted March 1, 2020; Epub March 15, 2020; Published March 30, 2020

In this article published in AJTR, a minor concern regarding the part of introduction section, page 3438 “Cenicriviroc (CVC), a CCR2/CCR5 co-inhibitor, is widely used in AIDS prevention and treatment” revised to “Cenicriviroc (CVC), a CCR2/CCR5 co-inhibitor, is widely studied in AIDS prevention and treatment”.

**Address correspondence to:** Xuefeng Xia, Department of General Surgery, The Affiliated Drum Tower

Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu Province, China. E-mail: danielxuefeng@hotmail.com; Wei Chen, Cancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China. E-mail: viogro@163.com